Insulin Human
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Insulin Human: From Diabetes Mellitus to Autoimmune Oophoritis
One-Sentence Summary
Insulin Human is the physiological hormone replacement used for insulin-dependent diabetes mellitus. The TxGNN model predicts it may be relevant to Autoimmune Oophoritis, but this ranking currently has no supporting clinical trials and no supporting literature — the association appears to reflect a shared autoimmune comorbidity pattern rather than a direct treatment mechanism.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diabetes Mellitus (well-established use; no local approved-indication text is available in this evidence pack) |
| Predicted New Indication | Autoimmune Oophoritis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for insulin human is not available in this evidence pack. Based on known clinical information, insulin human is the standard replacement therapy for insulin-dependent (Type 1) diabetes, restoring glucose uptake and metabolic regulation via the insulin receptor pathway.
Autoimmune oophoritis is one component of polyglandular autoimmune syndrome (APS) and can co-occur with Type 1 diabetes because the two conditions share an underlying autoimmune predisposition — not because insulin acts therapeutically on ovarian tissue. The TxGNN score most likely captures this comorbidity/co-occurrence pattern in the knowledge graph rather than a genuine pharmacological mechanism linking insulin to ovarian autoimmunity.
Given this, the prediction should be read as a hypothesis-generating signal only. No clinical trial, case report, or mechanistic study in the current evidence pack supports insulin as a treatment for autoimmune oophoritis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (autoimmune oophoritis) has zero clinical trials and zero literature support, and the proposed mechanistic link is a comorbidity association rather than a causal treatment pathway — this does not meet the bar to advance past S0.
To proceed, the following is needed:
- Direct mechanistic or preclinical evidence that insulin modulates ovarian autoimmune activity (not merely diabetes co-occurrence)
- At least one case series or observational study specifically evaluating insulin in autoimmune oophoritis
- TFDA/package-insert safety data (currently a blocking data gap — DG001) before any S1 safety screening can begin
- Formal MOA data from DrugBank (DG002) to support or refute the mechanistic rationale
Note on other candidates in this evidence pack: two lower-ranked predictions have notably stronger, direct mechanistic support than the top-ranked one and may warrant separate evaluation — thiamine-responsive dysfunction syndrome (rank 4) and pancreatic agenesis (rank 9), both scored "Proceed with Guardrails" because insulin is the established standard-of-care replacement therapy in the underlying genetic diabetes subtypes involved, even though formal trial data is still absent for both.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.